138 related articles for article (PubMed ID: 10554801)
61. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
62. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
[TBL] [Abstract][Full Text] [Related]
63. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
64. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
65. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
66. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
67. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
68. Cell cycle-dependent fluctuation of urokinase-type plasminogen activator, its receptor, and inhibitors in cultured bovine mammary epithelial and myoepithelial cells.
Zavizion B; White JH; Bramley AJ
Biochim Biophys Acta; 1998 Jun; 1403(2):141-50. PubMed ID: 9630579
[TBL] [Abstract][Full Text] [Related]
69. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
70. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
71. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
72. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
73. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
[TBL] [Abstract][Full Text] [Related]
74. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
75. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
Mustjoki S; Tapiovaara H; Sirén V; Vaheri A
Leukemia; 1998 Feb; 12(2):164-74. PubMed ID: 9519778
[TBL] [Abstract][Full Text] [Related]
76. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
[TBL] [Abstract][Full Text] [Related]
77. The imbalance of plasminogen activators and inhibitor in preeclampsia.
Gao M; Nakabayashi M; Sakura M; Takeda Y
J Obstet Gynaecol Res; 1996 Feb; 22(1):9-16. PubMed ID: 8624901
[TBL] [Abstract][Full Text] [Related]
78. Induction of the plasminogen activator system accompanies peripheral nerve regeneration after sciatic nerve crush.
Siconolfi LB; Seeds NW
J Neurosci; 2001 Jun; 21(12):4336-47. PubMed ID: 11404419
[TBL] [Abstract][Full Text] [Related]
79. Plasminogen activator system in human coronary atherosclerosis.
Raghunath PN; Tomaszewski JE; Brady ST; Caron RJ; Okada SS; Barnathan ES
Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1432-43. PubMed ID: 7670959
[TBL] [Abstract][Full Text] [Related]
80. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
Daneri-Navarro A; Macias-Lopez G; Oceguera-Villanueva A; Del Toro-Arreola S; Bravo-Cuellar A; Perez-Montfort R; Orbach-Arbouys S
Eur J Cancer; 1998 Mar; 34(4):566-9. PubMed ID: 9713310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
